Form 8-K AMARIN CORP PLC\UK For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/23/2026
Aegis Capital Comments on Amarin (AMRN) Following Q2 Results, Commercialization Update
August 8, 2014 9:23 AM EDTAegis Capital affirms its Buy rating and $2 price target on Amarin (Nasdaq: AMRN) following Q2 results.
Analyst Ram Selvaraju commented, [Amarin] recorded $12.6mm in Vascepa sales, below our estimate of $14mm. R&D expenses were $11.7mm, slightly above our forecast of $10mm, and SG&A expenses were $21.1mm, also above our projection of $18mm. While the firm reported earnings per share of $0.08 vs. our expectation of a... More

